You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
凱普生物(300639.SZ):控股子公司中標約4605.91萬元瀘州市衞生健康委員會全民健康工程婦幼疾病檢測服務採購項目
格隆匯 12-06 18:22

格隆匯12月6日丨凱普生物(300639.SZ)公佈,近日,公司控股子公司廣州凱普醫學檢驗所收到採購代理機構四川省禾益思遠工程項目管理有限公司發出的《中標通知書》。詳情如下:

項目名稱:瀘州市衞生健康委員會全民健康工程婦幼疾病檢測服務採購項目;主要成交標的信息:本項目為醫療服務採購項目,分為2個包,第1包為婦女宮頸癌預防(HPV病毒感染)檢測服務(2022-2024年),第2包為無創產前檢測(NIPT)(2021-2023年)。經評標委員會評審,廣州凱普醫學檢驗所被確定為該項目第一包中標供應商,中標價格為4605.91萬元,佔公司2020年經審計營業收入的3.40%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account